Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.42 Friday, 10th May 2024 CANF stock ended at $2.09. This is 2.42% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 3.29% from a day low at $2.05 to a day high of $2.12.
90 days $1.91 $2.71
52 weeks $1.81 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Nov 25, 2016 $2.16 $2.33 $2.11 $2.33 19 400
Nov 23, 2016 $2.20 $2.28 $2.10 $2.16 57 500
Nov 22, 2016 $2.23 $2.25 $2.16 $2.21 49 000
Nov 21, 2016 $2.35 $2.35 $2.20 $2.20 38 400
Nov 18, 2016 $2.35 $2.36 $2.21 $2.32 36 900
Nov 17, 2016 $2.33 $2.37 $2.23 $2.32 20 100
Nov 16, 2016 $2.29 $2.37 $2.21 $2.32 81 800
Nov 15, 2016 $2.23 $2.34 $2.22 $2.33 12 600
Nov 14, 2016 $2.36 $2.36 $2.20 $2.20 38 400
Nov 11, 2016 $2.22 $2.37 $2.17 $2.35 40 800
Nov 10, 2016 $2.25 $2.29 $2.22 $2.26 30 000
Nov 09, 2016 $2.40 $2.40 $2.17 $2.24 36 500
Nov 08, 2016 $2.23 $2.29 $2.10 $2.13 66 200
Nov 07, 2016 $2.29 $2.33 $2.21 $2.25 43 200
Nov 04, 2016 $2.27 $2.38 $2.19 $2.34 70 300
Nov 03, 2016 $2.33 $2.39 $2.17 $2.28 107 600
Nov 02, 2016 $2.38 $2.40 $2.21 $2.34 45 000
Nov 01, 2016 $2.39 $2.50 $2.32 $2.38 75 900
Oct 31, 2016 $2.35 $2.42 $2.32 $2.42 6 900
Oct 28, 2016 $2.50 $2.50 $2.26 $2.35 54 000
Oct 27, 2016 $2.35 $2.50 $2.26 $2.50 90 700
Oct 26, 2016 $2.34 $2.39 $2.27 $2.33 47 800
Oct 25, 2016 $2.45 $2.48 $2.30 $2.35 57 200
Oct 24, 2016 $2.38 $2.42 $2.33 $2.42 28 100
Oct 21, 2016 $2.36 $2.45 $2.33 $2.38 32 700
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT